Pfizer: Uterine Cervical Neoplasms trials
The registry lists 17 Uterine Cervical Neoplasms studies with Pfizer as lead sponsor. 3 are open to participants now and 8 have results posted.
Phase 1 9Phase 2 7Phase 3 1Phase 4 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Tucatinib Continuation StudyNot yet recruitingNCT07768358Phase 4
- Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerRecruitingNCT06952660Phase 4
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1
- Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical CancerCompletedNCT04697628Phase 3Results posted
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results posted
- A Trial of Tisotumab Vedotin in Cervical CancerCompletedNCT03438396Phase 2Results posted
- Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedNCT03245736Phase 2Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02552121Phase 1/2Results posted
- Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566CompletedNCT02315066Phase 1Results posted
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02001623Phase 1/2Results posted
- Irinotecan Study For Cervical CancerCompletedNCT00136955Phase 2Results posted
- A Study of SGN-ALPV in Advanced Solid TumorsTerminatedNCT05229900Phase 1
- A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerWithdrawnNCT04889495
- A Study of SGN-STNV in Advanced Solid TumorsTerminatedNCT04665921Phase 1
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
- Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerTerminatedNCT03786081Phase 1/2